“Orthopedic stem cells’ higher average selling price is better tolerated by the commercialized nature of the spine market,” said Dr. Kamran Zamanian, CEO of iData. “As new stem cell products and innovations enter the market, prices should decline, which will aid greater adoption and in turn fuel the number of procedures using stem cell bone grafts.”
Here are eight things to know:
1. The orthopedic stem cell market is the fastest growing orthopedic biomaterial segment in the United States.
2. Products in the orthopedic stem cell market aim to provide greater osteoinductive and osteogenesis properties compared to other bone grafts to improve bone repair.
3. The stem cells are currently only being used for spinal procedures, specifically lumbar and cervical indications, but the market could grow further as more competitors join the market and education on stem cell use improves for new indications being approved by the FDA.
4. The increased again population will mean more incidence of osteoarthritis and degenerative joint disease, which could drive stem cell therapies.
5. The cell-based therapies are currently very costly and developing stem cell products is prohibitively expensive.
6. Protein markers and definitions help distinguish types of stem cells, but they are challenging to develop as cells change in various clinical settings.
7. There is a potential reward for end-users, but the cost of research and development is a burden for entrants, which will hinder future growth.
8. NuVasive is the leader in the United States orthopedic stem cell market and they are currently shifting sales efforts to their second-generation product Osteocel Plus.
More articles on orthopedic devices:
22 spine devices receive FDA 510(k) clearance In April
MiMedx gets Novation’s Innovative Technology award: 5 things to know
K2M, Mazor, Amedica & more—12 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
